Back to top
more

Lyra Therapeutics (LYRA)

(Delayed Data from NSDQ)

$6.75 USD

6.75
9,196

+0.08 (1.20%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $6.86 +0.11 (1.63%) 4:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Lyra Therapeutics, Inc. (LYRA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Kinjel Shah headshot

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

by Kinjel Shah

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

Zacks Equity Research

Brookdale's (BKD) November 2023 Weighted Average Occupancy Up

by Zacks Equity Research

Brookdale (BKD) witnesses 25 straight months of year-over-year increase in weighted average occupancy level.

Zacks Equity Research

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical

by Zacks Equity Research

Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

Zacks Equity Research

Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up

by Zacks Equity Research

Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 25% and 11.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -5.93% and 15.19%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -22.22% and 28.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of -5% and 19.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -19.90% and 6.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 4.76% and 12.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of -26.47% and 92.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for August 20th

by Zacks Equity Research

ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.

Zacks Equity Research

New Strong Sell Stocks for August 12th

by Zacks Equity Research

WKHS, SPCE, PASG, LYRA, and GO have been added to the Zacks Rank #5 (Strong Sell) List on August 12, 2021

Zacks Equity Research

Why Earnings Season Could Be Great for Lyra Therapeutics (LYRA)

by Zacks Equity Research

Lyra Therapeutics (LYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.